If you’re planning real-world evidence research in Germany, the size of your dataset might matter less than you think. When study designs evolve mid-project or you need multiple analysis rounds, the access model you choose upfront determines whether you can adapt or start over.
Key Takeaways
The FDZ Gesundheit offers unmatched nationwide statutory health insurance coverage – roughly 74 million insured individuals – but operates within a legally defined, application-based framework that limits analytical flexibility.
Commercial claims data providers offer contractual access with the ability to refine study designs, run repeat analyses, and update findings without restarting a formal application process.
For iterative research programs – including real-world evidence (RWE), HEOR, and market access studies – operational flexibility can matter as much as dataset size.
The right choice depends on research objectives, timelines, and whether the study design is expected to evolve. The section below on decision questions can help clarify which pathway fits.
Germany’s health data landscape has changed significantly since the Health Data Use Act (Gesundheitsdatennutzungsgesetz, GDNG) came into force on March 26, 2024. Two distinct pathways now exist for accessing statutory health insurance (SHI) claims data – and choosing between them has real consequences for how a research project runs from start to finish.
Operational Flexibility Is the Real Differentiator
The instinct when comparing data sources is to focus on population size. Bigger dataset, better research – or so the logic goes. But for many pharmaceutical, HEOR, and health services research programs, the more decisive factor is how the data access model handles change: changes to study design, analytical scope, follow-up timelines, and the need to revisit earlier work.
That’s where the FDZ Gesundheit and commercial claims data providers diverge most sharply. The population coverage difference is real, but the workflow difference is what shapes day-to-day research delivery. MEDDDICAL’s German health data provider comparison breaks down both pathways in detail – useful context before committing to either route.
The question is therefore not simply which dataset is larger, but which access model fits the research objective, timeline and analytical requirements. Choosing between statutory and commercial data sources requires looking at these factors together.
How the FDZ Gesundheit Actually Works
Nationwide Coverage, Strict Governance
The FDZ Gesundheit – also referred to as the Health Data Lab (HDL) at the BfArM – officially launched in its current form on October 9, 2025. It provides access to pseudonymized billing data from all statutory health insurers across Germany, coordinated through the National Association of Statutory Health Insurance Funds. Coverage spans approximately 74 million individuals across roughly 95 insurers, with longitudinal records available from multiple prior years.
That kind of nationwide scope is genuinely difficult to replicate. For rare disease research or any question requiring maximum case ascertainment without statistical extrapolation, the FDZ’s population base is a meaningful scientific advantage.
But the governance structure reflects the data’s sensitivity. Researchers never receive raw data. All analysis happens within a secure processing environment – a controlled server setup where only final, reviewed outputs leave the system. The FDZ adheres strictly to the principle of data minimization: researchers access only what is necessary for the approved research question, nothing more.
What the Application Process Locks In
Access begins with a formal application, assessed against the legally permitted research purposes defined under the GDNG. The research question, data requirements, and analytical scope are all specified upfront. Once approved, those parameters form the operational boundary of the project.
This structure is not a bureaucratic inconvenience – it is a defining feature of statutory access. The FDZ exists to serve legally defined public-interest research, and the application process is what makes that accountability possible. The trade-off is a relatively rigid project envelope established before any data has been seen.
Where FDZ Constraints Hit Iterative Research
Study Design Is Fixed After Approval
In practice, research rarely unfolds exactly as planned. Preliminary results raise new questions. Inclusion criteria turn out to need adjustment. A hypothesis shifts when early data patterns don’t match expectations. These are normal parts of applied research – and they require the ability to adapt.
Under the FDZ framework, the approved application defines what analysis is permissible. Study design changes after approval are not straightforwardly accommodated; modifications that go beyond the original scope typically require revisiting the application process. For a study that is designed once and executed linearly, this is manageable. For iterative programs, it introduces meaningful friction.
New Analyses Mean Restarting the Clock
Follow-up analyses, study extensions, or updated evidence submissions – common in pharmaceutical market access and ongoing evidence generation – can require separate applications under the FDZ model. Each new application resets the administrative timeline. For programs where regulatory submissions, publication schedules, or commercial decisions depend on findings, unpredictable access windows create real project risk.
The FDZ’s secure environment also operates on scheduled access periods, meaning researchers cannot simply log in and run an additional query when a new question arises. Output review processes add further lead time before results can be used.
Access to the FDZ Gesundheit is governed by specific eligibility and research-purpose requirements. For a detailed explanation of the process, see How to Access German Claims Data under the GDNG.
What Commercial Providers Do Differently
Contractual Access vs. Statutory Application
Commercial claims data providers in Germany maintain large longitudinal databases drawn from statutory health insurance data – some covering several million insured individuals with records extending back multiple years. Access is established through a commercial agreement rather than a statutory application, which changes the research relationship from the start.
There is no legally defined research purpose requirement to satisfy. The scope of the agreement is negotiated rather than prescribed, and the analytical environment – typically a remote access setup managed by the provider – is available on a project basis rather than a scheduled-window basis.
Iterative Refinement Without Process Restarts
The operational implication is significant. When early results prompt a refinement to the cohort definition, or when a client requests an updated analysis for a resubmission, commercial providers can generally accommodate that within the existing project framework. Study design adjustments, repeat analyses, and follow-up work do not typically require restarting the access process.
For real-world evidence programs, HEOR projects, and market access dossiers – where multiple rounds of analysis and reporting are the norm – this flexibility reduces project risk and supports more predictable delivery timelines. Rapid study initiation is also more reliably achievable, since there is no application review period standing between project kick-off and first data access.
When Nationwide Coverage Outweighs Flexibility
None of this makes commercial providers the automatic choice. There are research scenarios where the FDZ’s nationwide coverage is the deciding factor – and where the operational constraints are worth accepting.
Rare disease studies, where patient populations are small and every additional observation meaningfully affects statistical confidence, benefit most from the FDZ’s national data. Studies where avoiding extrapolation from a sample is scientifically important – such as epidemiological work informing national policy – are also better suited to the FDZ’s scope. Where the research question is clearly defined upfront, unlikely to change, and falls squarely within the GDNG’s permitted purposes, the application-based model is a workable path.
A commercial database of several million insured individuals provides sufficient statistical power for many common disease and healthcare utilization studies. For those projects, the incremental precision of nationwide coverage may not justify the additional process overhead. But for the cases where it does, the FDZ is the right tool.
Choosing the Right Pathway for Your Project
Questions That Clarify the Decision
Before committing to either access model, a structured set of questions tends to surface the right answer quickly:
- Does the study qualify under the GDNG’s legally permitted research purposes? If not, the FDZ is not an option regardless of its other merits.
- Is nationwide population coverage scientifically necessary? For rare diseases or policy-level epidemiology, yes. For many HEOR and market access studies, a large commercial sample is sufficient.
- How quickly are results needed? Commercial providers support faster initiation; the FDZ application and review process adds lead time.
- Is the study design likely to evolve? If analytical refinement is anticipated, the commercial model handles that more smoothly.
- Are multiple analyses or study updates expected? Ongoing evidence generation programs almost always benefit from the commercial pathway’s repeat-access model.
- Are internal resources available to manage a statutory application process? The FDZ process is manageable but requires dedicated administrative effort – a real resource consideration for smaller teams.
Match Your Data Source to Your Research Workflow
The FDZ Gesundheit and commercial claims data providers are not competing for the same research programs – they serve different operational realities. The FDZ is purpose-built for legally defined public-interest research requiring national coverage. Commercial providers are built for research programs that need speed, flexibility, and the ability to evolve.
Treating one as universally superior misses the point. The question is which model fits the research workflow – and answering that honestly at the outset saves significant time, cost, and frustration downstream.
For researchers working within Germany’s evolving health data ecosystem, MEDDDICAL provides expert guidance on accessing and working with German SHI claims data across both statutory and commercial pathways at medddical.com/health-insurance-datasets/german-health-data-providers-claims-data-gdng/.
